Lipomeg (Omega-3-Acid Ethyl Esters)

After oral ingestion, the ethyl ester forms are hydrolysed to release EPA and DHA, the active omega‑3 fatty acids. These molecules inhibit hepatic triglyceride synthesis, reduce VLDL secretion, and increase fatty‑acid oxidation, leading to a net decrease in circulating triglycerides.

The appropriate dose of Lipomeg is determined by the prescribing healthcare professional based on the patient’s triglyceride levels, overall cardiovascular risk, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for Lipomeg in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To order Lipomeg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

Lipomeg provides omega‑3‑acid ethyl esters, a concentrated form of EPA and DHA that may achieve higher plasma levels compared with standard fish‑oil triglyceride preparations. This can result in more pronounced triglyceride reduction, especially at higher prescribed doses, while maintaining a similar safety profile.

Store Lipomeg at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in areas with high humidity or direct sunlight, and keep out of reach of children.

Lipomeg is taken orally, usually with a meal to improve absorption. The capsules or tablets should be swallowed whole with water and not crushed or chewed, unless the prescribing information specifically allows an alternative method.

Serious adverse events, although rare, include pancreatitis, severe allergic reactions such as anaphylaxis, significant elevations in liver enzymes, and increased bleeding, particularly when combined with anticoagulant therapy. Patients should seek immediate medical attention if they experience abdominal pain, rash, swelling, or unusual bruising.

Lipomeg should be avoided in individuals with a known hypersensitivity to omega‑3 fatty acids or fish/shellfish products, patients with active bleeding disorders, and those taking high‑dose anticoagulants without close monitoring. It is also contraindicated in patients with severe liver disease until further evaluation by a physician.